Atrium Therapeutics

RNA · NASDAQ

$7.98+$0.37 (+4.86%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $7.61

RNA analyst rating

HoldConsensus of 12 analysts over the last 12 months. 33% rate it a buy.

Strong buy0
Buy4
Hold8
Underperform0
Sell0

12-month price target · 5 analysts

Average $25.50 (+219.5% upside)

Low: $25.25
Now: $7.98
High: $26.25

Upgrades and downgrades

The latest rating actions, newest first

RNA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Aug 14, 2026	Maintains	Buy	$25.00	32%
HC Wainwright & Co.	Aug 6, 2026	Initiates	Buy	$25.00	32%
Cantor Fitzgerald	Jun 18, 2026	Initiates	Overweight	$25.00	41%
Leerink Partners	May 15, 2026	Initiates	Outperform	$25.00	34%
Wells Fargo	Mar 11, 2026	Initiates	Overweight	$25.00	32%
Chardan Capital	Nov 11, 2025	Maintains	Neutral	$72.00	38%
TD Cowen	Oct 29, 2025	Downgrade	Buy → Hold	$78.00 → $74.00	42%
Chardan Capital	Oct 28, 2025	Downgrade	Buy → Neutral	$75.00 → $72.00	38%
RBC Capital	Oct 28, 2025	Downgrade	Outperform → Sector Perform	$61.00 → $72.00	44%
Citigroup	Oct 27, 2025	Downgrade	Buy → Neutral	$75.00 → $72.00	60%

The case for and against

Updated Oct 17, 2026

Bull case

Atrium Therapeutics is attractive because its AOC platform is externally validated, with Avidity’s prior clinical success de-risking the core delivery concept and supporting the idea that heart-targeted RNA degradation can translate into meaningful biology. The lead program ATR 1072 has a first-mover position in PRKAG2 syndrome, where there are no approved therapies, while preclinical data showing ~85% cardiac mRNA reduction in NHPs and functional improvement in mice supports a credible disease-modifying thesis; ATR 1086 adds a second shot on goal in PLN cardiomyopathy with similar target engagement and survival benefit. Financially, the company expects a second $15M Bristol-Myers Squibb milestone in 3Q26 and has cash runway through mid-2028, giving it time to reach initial proof-of-concept data in 2H27 and broaden the pipeline.

Bear case

Atrium Therapeutics is fundamentally risky because its entire investment case depends on unproven RNA delivery to heart tissue, where insufficient myocardial exposure, weak target knockdown, or short durability could undermine both ATR 1072 and ATR 1086. Despite $267.8 million in cash and cash equivalents at March 31, 2026, management only expects funding through key proof-of-concept milestones, while clinical spending, slower enrollment, and possible delays in development or reimbursement could force additional financing and dilution. The bearish view is reinforced by safety and commercial uncertainty, including potential cardiac, immune, hepatic, renal, or hematologic toxicity, unknown consequences of suppressing PRKAG2 or PLN biology, and competition from AZD4063, TN-501, and other gene-therapy or oligonucleotide approaches.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.